Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 2,105–2,112 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Incyte Corporation ZYNYZ (retifanlimab-dlwr) - (POD1UM-304) Non-small cell lung cancer (NSCLC) PDUFA Data Released Intravenous Oncology
Incyte Corporation MRGPRX2 (INCB000262) Spontaneous urticaria (CSU) Phase 2 Clinical Pause Intravenous Immunology
Incyte Corporation Pelareorep and retifanlimab (INCMGA00012) - (IRENE) Triple-negative breast cancer Phase 2 Trial Completed Intravenous Oncology
Incyte Corporation INCB99280 High risk resectable cutaneous squamous cell carcinoma (CSCC) Phase 2 Trial Planned oral Oncology
Incyte Corporation MRGPRX4 (INCB000547) Cholestatic pruritus (CP) Phase 2 Trial Discontinued Oral Gastroenterology
Indivior Pharmaceuticals Inc. INDV-2000 Opioid Use Disorder (OUD) Phase 2 Ongoing Oral Anti-Addiction
Indivior Pharmaceuticals Inc. INDV-6001 Opioid Use Disorder (OUD) Phase 2 Ongoing Oral Anti-Addiction
Indivior Pharmaceuticals Inc. AEF0117 Cannabis-Related Disorders (CrD) Phase 2b Data Released Oral Psychiatric